JP2022514116A5 - - Google Patents

Info

Publication number
JP2022514116A5
JP2022514116A5 JP2021546487A JP2021546487A JP2022514116A5 JP 2022514116 A5 JP2022514116 A5 JP 2022514116A5 JP 2021546487 A JP2021546487 A JP 2021546487A JP 2021546487 A JP2021546487 A JP 2021546487A JP 2022514116 A5 JP2022514116 A5 JP 2022514116A5
Authority
JP
Japan
Application number
JP2021546487A
Other languages
Japanese (ja)
Other versions
JP2022514116A (ja
JPWO2020079448A5 (https=
JP7712207B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2019/052980 external-priority patent/WO2020079448A1/en
Publication of JP2022514116A publication Critical patent/JP2022514116A/ja
Priority to JP2022173369A priority Critical patent/JP7762132B2/ja
Publication of JPWO2020079448A5 publication Critical patent/JPWO2020079448A5/ja
Publication of JP2022514116A5 publication Critical patent/JP2022514116A5/ja
Priority to JP2024212437A priority patent/JP2025041678A/ja
Application granted granted Critical
Publication of JP7712207B2 publication Critical patent/JP7712207B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021546487A 2018-10-19 2019-10-18 新規な癌抗原及び方法 Active JP7712207B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022173369A JP7762132B2 (ja) 2018-10-19 2022-10-28 新規な癌抗原及び方法
JP2024212437A JP2025041678A (ja) 2018-10-19 2024-12-05 新規な癌抗原及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18201634.5 2018-10-19
EP18201634 2018-10-19
PCT/GB2019/052980 WO2020079448A1 (en) 2018-10-19 2019-10-18 Novel cancer antigens and methods

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022173369A Division JP7762132B2 (ja) 2018-10-19 2022-10-28 新規な癌抗原及び方法
JP2024212437A Division JP2025041678A (ja) 2018-10-19 2024-12-05 新規な癌抗原及び方法

Publications (4)

Publication Number Publication Date
JP2022514116A JP2022514116A (ja) 2022-02-09
JPWO2020079448A5 JPWO2020079448A5 (https=) 2022-11-10
JP2022514116A5 true JP2022514116A5 (https=) 2022-11-10
JP7712207B2 JP7712207B2 (ja) 2025-07-23

Family

ID=64183836

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021546487A Active JP7712207B2 (ja) 2018-10-19 2019-10-18 新規な癌抗原及び方法
JP2022173369A Active JP7762132B2 (ja) 2018-10-19 2022-10-28 新規な癌抗原及び方法
JP2024212437A Pending JP2025041678A (ja) 2018-10-19 2024-12-05 新規な癌抗原及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022173369A Active JP7762132B2 (ja) 2018-10-19 2022-10-28 新規な癌抗原及び方法
JP2024212437A Pending JP2025041678A (ja) 2018-10-19 2024-12-05 新規な癌抗原及び方法

Country Status (12)

Country Link
US (2) US12263216B2 (https=)
EP (1) EP3866827A1 (https=)
JP (3) JP7712207B2 (https=)
KR (1) KR20210080372A (https=)
CN (2) CN119978090A (https=)
AU (1) AU2019360427A1 (https=)
BR (1) BR112021006941A2 (https=)
CA (1) CA3112427A1 (https=)
EA (1) EA202191081A1 (https=)
IL (1) IL282308A (https=)
MX (1) MX2021004453A (https=)
WO (1) WO2020079448A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021006941A2 (pt) 2018-10-19 2021-08-31 The Francis Crick Institute Limited Antígenos de câncer inovadores e métodos
AU2020302285A1 (en) * 2019-06-28 2021-12-02 Enara Bio Limited Novel cancer antigens and methods
CN116057067A (zh) * 2020-04-17 2023-05-02 弗朗西斯·克里克研究所有限公司 用于治疗黑素瘤的ctl抗原的融合蛋白
JP2023522193A (ja) * 2020-04-17 2023-05-29 ザ フランシス クリック インスティチュート リミティッド 抗原プール

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002515734A (ja) 1996-01-02 2002-05-28 カイロン コーポレイション 遺伝子改変された樹状細胞により媒介される免疫刺激
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
US7504490B1 (en) 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
AU2001238347A1 (en) 2000-02-28 2001-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US20020015998A1 (en) 2000-04-06 2002-02-07 Gabriel Vogeli Novel G protein-coupled receptors
US20020082206A1 (en) 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
JP2003304877A (ja) 2002-04-15 2003-10-28 Keio Gijuku ヒト色素細胞特異分子
WO2004038003A2 (en) 2002-10-25 2004-05-06 Five Prime Therapeutics, Inc. Human polypeptides encoded by polynucleotides and methods of their use
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
DK1871391T3 (da) 2005-03-30 2012-04-16 Viroxis Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
WO2006105642A1 (en) 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
AT502292B1 (de) 2005-05-11 2010-04-15 Avir Green Hills Biotechnology Melanomdiagnose
US20070072175A1 (en) 2005-05-13 2007-03-29 Biogen Idec Ma Inc. Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof
EP1963534A2 (en) 2005-12-19 2008-09-03 Genizon Biosciences Inc. Genemap of the human gene associated with crohn's disease
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
US20090297530A1 (en) 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
US20100120627A1 (en) 2006-08-02 2010-05-13 Abdelmajid Belouchi Genemap of the human genes associated with psoriasis
EP2118320A4 (en) 2007-02-06 2010-05-19 Genizon Biosciences Inc GENE CARD OF HUMAN GENES ASSOCIATED WITH HYPERACTIVITY ATTENTION DEFICIT DISORDER (ADHD)
US8541553B2 (en) 2007-05-24 2013-09-24 Baxter Healthcare Sa Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein
WO2009026116A2 (en) 2007-08-16 2009-02-26 Genizon Biosciences, Inc. Genemap of the human genes associated with longevity
WO2009039244A2 (en) 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
EP2340851A4 (en) 2008-09-18 2012-09-26 Univ Keio DIAGNOSTIC METHOD AND THERAPEUTIC METHOD FOR CANCER
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
TW201326481A (zh) 2011-08-30 2013-07-01 Nat Defense Medical Ct 預測易罹患卵巢贅瘤或卵巢癌預後之生物標記
FR2984362B1 (fr) 2011-12-20 2017-11-24 Biomerieux Sa Procede pour le diagnostic ou le pronostic in vitro du cancer du poumon
WO2014004385A2 (en) 2012-06-25 2014-01-03 Board Of Regents, The University Of Texas System Anti-cancer vaccines
ES2807791T3 (es) 2014-12-08 2021-02-24 Univ Michigan Regents ARN no codificantes y usos de los mismos
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
CR20180551A (es) 2016-04-21 2019-02-12 Immatics Biotechnologies Gmbh Inmunoterapia contra el melanoma y otros tipos de cáncer
EP3576751A4 (en) 2017-02-01 2021-08-04 ModernaTX, Inc. RNA ANTI-CANCER VACCINES
BR112021006941A2 (pt) 2018-10-19 2021-08-31 The Francis Crick Institute Limited Antígenos de câncer inovadores e métodos
AU2020302285A1 (en) 2019-06-28 2021-12-02 Enara Bio Limited Novel cancer antigens and methods
MX2021015766A (es) 2019-06-28 2022-01-27 The Francis Crick Institute Ltd Nuevos antigenos y metodos contra el cancer.
WO2021005338A2 (en) 2019-07-05 2021-01-14 The Francis Crick Institute Limited Novel cancer antigens and methods
JP7834016B2 (ja) 2019-07-05 2026-03-23 ザ フランシス クリック インスティチュート リミティッド 新規な癌抗原及び方法

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
AU2020104490A5 (https=)
BR112021018452A2 (https=)
BR112021018102A2 (https=)
BR112019016138A2 (https=)
BR112019016142A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021017173A2 (https=)
BR112021017083A2 (https=)
BR112021018250A2 (https=)
BR112021018584A2 (https=)
BR112021017310A2 (https=)